Innovating to improve health worldwide

Ensuring harmonized approaches to life cycle assessment of health products

The global innovative pharmaceutical industry recognizes the increasing interest from health systems, procurers, and policymakers in understanding the environmental footprint of medicines and vaccines. As conversations evolve around product-level life cycle assessment (LCA), it is vital that any emerging frameworks support clarity, methodological consistency, and insights that enable companies to improve their own environmental performance....

Statement at the fifth meeting of the open-ended Intergovernmental Working Group (IGWG 5) on the WHO Pandemic Agreement

On 9 February 2026 in Geneva, IFPMA delivered a statement at the fifth meeting of the open-ended Intergovernmental Working Group (IGWG 5) on the WHO Pandemic Agreement.

158th session of the WHO Executive Board (EB158): Reform of the global health architecture and the UN80 initiative

On 6 February 2026, IFPMA delivered a statement on Agenda item 29.1 on reform of the global health architecture at the 158th session of the WHO Executive Board in Geneva. The innovative pharmaceutical industry views this process as a critical opportunity to build a stronger, truly fit-for-purpose global health architecture. As a trusted and official...

158th session of the WHO Executive Board: WHO’s work in health emergencies

We appreciate the opportunity to contribute to the discussions at EB158. WHO’s work on strengthening emergency preparedness reflects a shared commitment to ensuring the world is better equipped for future health threats. We welcome this direction and the emphasis on clarity, coordination, and readiness. As EB158 documents highlight, WHO will now take on an expanded set of responsibilities...